Oncology · Biliary Tract CancerTrial Updateclinicalmid-term

Phase II Trial of Binimetinib with mFOLFOX6 in Advanced Biliary Tract Cancers

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/26/2026, 12:34:57 PM

Assessment confidence: 68% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase II trial of binimetinib combined with mFOLFOX6 represents a significant opportunity to enhance treatment options for advanced biliary tract cancers. Success in this trial could strengthen binimetinib's position within the oncology portfolio and influence competitive dynamics in the market. Regulatory context from FDA (FDA TA — BINIMETINIB (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (11 high-relevance).

Strategic Assessment

Success in this trial may enhance the strategic positioning of binimetinib in the oncology portfolio, particularly for advanced biliary tract cancers. The strongest clinical anchor is Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (ClinicalTrials.gov), entity match (binimetinib); patient population match (advanced). In Oncology · Biliary Tract Cancer, 4 regulatory and 4 competitive items passed relevance filtering for binimetinib.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer); patient population match (advanced). Secondary pressure from Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — BINIMETINIB (ORIG) (FDA). Entity match (binimetinib); Regulatory pathway relevance (nda). Positive trial results may lead to new regulatory filings, impacting approval timelines and labeling for binimetinib in the second-line treatment of advanced biliary tract cancers.

Key Risks

Elevated medium regulatory exposure for binimetinib could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, this trial could lead to increased market share for binimetinib in a challenging treatment landscape, potentially generating additional revenue streams for the company.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Oncology · Immunotherapy · Trial Update · If durvalumab demonstrates a significant survival benefit, it could position AstraZeneca favorably against competitors in the NSCLC immunotherapy space.
Oncology · Burkitt Lymphoma · Trial Update · If successful, this combination could position epcoritamab as a key treatment option in a challenging lymphoma subtype, impacting current therapies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any subsequent regulatory filings or partnerships that may arise from the findings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — BINIMETINIB (ORIG)
FDAhigh relevance
Entity match (binimetinib); Regulatory pathway relevance (nda)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ClinicalTrials.govhigh relevance
Entity match (binimetinib); Patient population match (advanced)
FDA document
View source
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (advanced)
FDA document
View source
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (advanced)
FDA document
View source
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
ClinicalTrials.govmedium relevance
Patient population match (advanced)
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer); Patient population match (advanced)
Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
Epcoritamab Shows Promise in High-risk Burkitt Lymphoma with DA-EPOCH-R in Phase II Trial
Humanexa Signalsmedium relevance
Moderate corpus alignment
Cadonilimab Targets PD-1/PD-L1 Blockade-Refractory MSI-H/dMMR Colorectal Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Clinical research progress and challenges of vaccine for human papillomavirus-associated cancers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

binimetinib
National Cancer Institute

Commercial impact

medium

If successful, this trial could lead to increased market share for binimetinib in a challenging treatment landscape, potentially generating additional revenue streams for the company.

Regulatory impact

medium

Positive trial results may lead to new regulatory filings, impacting approval timelines and labeling for binimetinib in the second-line treatment of advanced biliary tract cancers.

What to watch

Monitor trial results and any subsequent regulatory filings or partnerships that may arise from the findings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.